Aerska Therapeutics secured $39 million in follow‑on financing to advance its brain‑shuttle platform that ferries siRNA past the blood‑brain barrier by hitching payloads to antibodies mimicking iron uptake. Founders include Jack O’Meara and Alnylam alumnus Stuart Milstein; the company aims to silence disease genes in the brain by exploiting transferrin/iron transport mechanisms. Aerska’s approach packages siRNA with antibody conjugates to target the highly vascularized brain and enable intracellular delivery. The round — unusually rapid after its first financing — signals investor appetite for BBB delivery solutions and gene‑silencing strategies for neurological diseases.